Compare · MDLN vs NEPH
MDLN vs NEPH
Side-by-side comparison of Medline Inc. (MDLN) and Nephros Inc. (NEPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NEPH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 1260.1x NEPH ($38.2M).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 2 for NEPH).
- MDLN has more recent analyst coverage (25 ratings vs 1 for NEPH).
- Company
- Medline Inc.
- Nephros Inc.
- Price
- $35.95-1.74%
- $3.61+1.40%
- Market cap
- $48.08B
- $38.2M
- 1M return
- -
- -18.23%
- 1Y return
- -
- -26.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 1
Nephros Inc.
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest NEPH
- SEC Form DEF 14A filed by Nephros Inc.
- SEC Form 8-K filed by Nephros Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nephros Inc.
- SEC Form SCHEDULE 13G filed by Nephros Inc.
- Large owner Wexford Capital Lp disposed of $89,704 worth of shares (3,377,821 units at $0.03) (SEC Form 4)
- Director Amron Arthur H acquired $89,704 worth of shares (43,295 units at $2.07), increasing direct ownership by 13% to 158,623 units (SEC Form 4)
- Large owner Wexford Capital Lp exercised 812 shares at a strike of $3.60 (SEC Form 4)
- SEC Form 10-Q filed by Nephros Inc.
- Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026
- Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition